Please login to the form below

Not currently logged in

J&J and LDC to join forces on unmet medical needs

Collaboration will aim to find and accelerate new potential treatments

Johnson & Johnson headquarters 

Johnson & Johnson and the Lead Discovery Center (LDC) have collaborated to support drug candidates for highly unmet medical needs.

The two-year collaboration will aim to identify and accelerate potential candidates for the treatment and prevention of diseases that are shown to require further research and attention.

The LDC and J&J's London Innovation Centre will look into ongoing translational research opportunities sourced from the former's academic network, including institutes from the Max Planck Society, the Helmholtz Association and universities.

Dr Bert Klebl, CEO of the LDC, commented: “Through our academic network, we have access to a broad range of exciting molecular targets, pathobiological mechanisms and new therapeutic approaches which are the basis for project proposals with a high innovation potential for drug discovery.

“Together with Johnson & Johnson Innovation, we will now be able to offer a solution for more of our academic partners to translate their innovative findings into benefit for patients.”

J&J will review the candidates with the aim to discovery drugs that can make an impact on patients. For each project selected, the partners with negotiate a collaboration agreement for its joint development at the LDC.

Article by
Kirstie Pickering

12th June 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

When is it time to rebrand?
The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....